RA0240

antibody from Oursmab

Targeting: F12

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0240

Provider

Oursmab

Product name

Garadacimab (Biosimilar Reference Antibody) (F12)

Antibody type

Monoclonal

Description

Garadacimab (development code CSL-312 or Factor XIIa mAb) is an investigational, fully human monoclonal antibody being developed for the preventive treatment of hereditary angioedema (HAE) attacks. It represents a novel, targeted approach to HAE therapy. Garadacimab functions as a highly selective inhibitor of activated Factor XII (Factor XIIa). By binding with high affinity to Factor XIIa, it blocks its enzymatic activity. This inhibition prevents Factor XIIa from initiating the contact activation pathway (also known as the intrinsic pathway) of the coagulation cascade. Since this pathway is the primary driver of excessive bradykinin production in HAE, garadacimab aims to prevent the formation of bradykinin at its source, thereby reducing the frequency and severity of HAE attacks.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.